Is leprosy blindness avoidable? The effect of disease type, duration, and treatment on eye damage from leprosy in Uganda.

Waddell, Keith; Saunderson, Paul

doi:10.1136/bjo.79.3.250

Cited by 25 publications

(15 citation statements)

References 17 publications

(2 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Among 19 Nepali PB patients undergoing cataract surgery, 11 had cellular inflammatory infiltrations in the iris. A survey in Uganda 23 found clinical evidence of chronic uveitis in 16 of 364 (4.4%) patients with PB disease. These cases were generally older and had a longer duration of disease than PB patients without chronic uveitis.…”

Section: Uveal Disease (And Complicated Cataract)mentioning

confidence: 98%

“…Data from Uganda showed that leprosy patients with evidence of chronic uveitis have a 3-fold risk (95% CI 1.6, 5.5) of cataract, independent of age. 23 The incidence of acute uveitis in leprosy patients is not known but MB patients during type II reaction are at an increased risk of this. Among 25 Indian patients undergoing type II reaction, only 1 patient had acute uveitis, whereas an additional 2 to 3 patients had subacute uveitis.…”

Section: Uveal Disease (And Complicated Cataract)mentioning

confidence: 99%

See 1 more Smart Citation

A Overview of Ocular Leprosy After 2 Decades of Multidrug Therapy

Lewallen

Courtright²

2007

International Ophthalmology Clinics

View full text Add to dashboard Cite

Section: Uveal Disease (And Complicated Cataract)mentioning

confidence: 98%

Section: Uveal Disease (And Complicated Cataract)mentioning

confidence: 99%

A Overview of Ocular Leprosy After 2 Decades of Multidrug Therapy

Lewallen

Courtright²

2007

International Ophthalmology Clinics

View full text Add to dashboard Cite

“…A similar assessment of cataract surgical coverage among inhabitants of leprosy settlements in Nigeria was 44% (23/52 patients, cutoff point VAo0.05). 12 Reasons for not having had surgery in the Korean study (VAo0.3) were 'cataract not mature' in 28/48 (58%) patients, and 'no felt need' in 9/48 (19%) patients. In Nigeria, the main reasons for not having had surgery were 'costs' in 38/107 (36%), 'no service available' in 26 (24%), 'no felt need' in 19 (18%) (mainly unilateral cataract), 'unawareness of treatment' in 10 (9%), and fear in nine (8%) of patients.…”

Section: Cataractmentioning

confidence: 99%

“…The role of chronic uveitis in unclear, but may triple the risk of cataract. 12 The quoted studies all illustrate the high prevalence of cataract as a cause of blindness or severe visual impairment. With increased life expectancy, also for leprosy patients, numbers of cataract blind can be expected to further increase.…”

Section: Cataractmentioning

confidence: 99%

Prevention of blindness in leprosy and the role of the Vision 2020 Programme

Hogeweg

Keunen

2005

Eye

View full text Add to dashboard Cite

show abstract

“…3,4 The prevalence of blindness due to leprosy has been variously estimated as being 4.7% in India, 9 1.6% in Nigeria, 10 1.3% in China, 11 1.2% in Nepal 12 and 0.6% in Uganda. 13 A selected groups of leprosy affected individuals in hospitals or leprosaria are known to have a high frequency of multiple complications. 9,14,15 …”

Section: Introductionmentioning

confidence: 99%

Ocular Morbidity Among Leprosy Patients at a Leprosy Centre

Shrestha

et al. 2018

Med. J. Shree Birendra Hosp.

View full text Add to dashboard Cite

This work is licensed under creative common license: http://creativecommons.org/licenses/by-nc-nd/4.0/ © MJSBH 2018 ABSTRACT Introduction: Leprosy is one of the dreaded communicable disease due to its profound morbidity. In earlier days in Nepal, a different settlement was designated for leprosy patient and their families.Khokana of Lalitpur district of Nepal is one of them. The study was conducted to determine ocular morbidity among leprosy patients who had completed multi drug therapy. Methods:It was descriptive, quantitative and cross sectional study conducted at Khokana Leprosy Centre in Lalitpur district of Nepal. Leprosy patients who had completed multi drug therapy and consenting for the study were enrolled. Convenience sampling was done and the sample size was 70. After detail ophthalmic evaluation, socio-demographic profile of the participants and their ocular morbidities were documented and analysed.Results: Major findings were superciliary madarosis (78.57%), ciliary madarosis (61.4%), different grades of cataract (67.10% right eye and 60% left eye), pseudophakia (30% right eye and 37.10% left eye), tylosis (44.3%), corneal hypoesthesia (10% unilaterally and 15.7% bilaterally) and dry eye (10%).Entropion was present in 2.9% both unilaterally and bilaterally. Ectropion was present in 5.7% unilaterally and 10% bilaterally. Trichiasis was present in 1.4% unilaterally and 2.9% bilaterally.Similarly, eyelid nodule was present in 7.1% unilaterally and 1.4% bilaterally. Incomplete closure of the lids was present in 8.6% unilaterally and 2.9% bilaterally. Exposure keratitis was present in 7.1% unilaterally and 1.4% bilaterally, corneal opacity in 2.9% unilaterally and 1.4% bilaterally and corneal perforation in 2.9% unilaterally. Chronic iridocyclitis was present in 2.9% cases. Retinal pearls were seen in 2.86% of cases. According to WHO criteria of blindness, 2.9% patients were blind in the present study. 14 persons were unilaterally blind and among them, two had severe visual impairment in the other eye, eight had other eye moderate visual impairment and four had other eye mild visual impairment. Conclusions:Lid abnormalities, corneal abnormalities and cataract were the commonly encountered ocular morbidities among treated leprosy patients.

show abstract

Is leprosy blindness avoidable? The effect of disease type, duration, and treatment on eye damage from leprosy in Uganda.

Cited by 25 publications

References 17 publications

A Overview of Ocular Leprosy After 2 Decades of Multidrug Therapy

A Overview of Ocular Leprosy After 2 Decades of Multidrug Therapy

Prevention of blindness in leprosy and the role of the Vision 2020 Programme

Ocular Morbidity Among Leprosy Patients at a Leprosy Centre

Contact Info

Product

Resources

About